CRN safe nutrient intake
This article was originally published in The Tan Sheet
Vitamin and Mineral Safety 2nd Edition provides "supportable data" on safe levels of vitamin and mineral intake that is "far preferable" to Recommended Daily Allowances at a time when Codex Alimentarius is debating science-based standards for supplement regulation, the Council for Responsible Nutrition announces July 30. The publication is a quantitative risk assessment meant to "identify the highest chronic supplemental intake of vitamins and minerals that can be confidently asserted to pose no risk for the majority of the normal adult population," according to author John Hathcock, PhD, VP-scientific & international affairs, who also wrote the first edition in 1997 (1"The Tan Sheet" July 28, 1997)...
You may also be interested in...
VITAMIN E "NO OBSERVED ADVERSE EFFECT LEVEL" OF 80 TIMES RDA PROPOSED BY CRN in a July 8 report entitled "Vitamin and Mineral Safety." The Council for Responsible Nutrition asserts in the report its long-held contention that the Recommended Dietary Allowances set forth by the Food & Nutrition Board of the National Academy of Sciences are "not a valid basis for identifying safe upper intakes of vitamins and minerals." The report provides alternative methods for identifying safe upper nutrient intakes based on the use of "No Observed Adverse Effect Level" (NOAEL) and "Lowest Observed Adverse Effect Level" (LOAEL) values for 25 specific nutrients
BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.